Skip to main content

Table 1 Current clinical trials used CHOP as backbone

From: Molecular insights into pathogenesis and targeted therapy of peripheral T cell lymphoma

Title

NCT Number

Conditions

Status

Interventions

Lenalidomide in combination with CHOP in patients with untreated PTCL

NCT04423926

PTCL, NOS

AITL

ALK− ALCL

Phase III–IV ALK+ ALCL

EATL

Recruiting

Phase 1/Phase 2

Drug: Lenalidomide

Drug: Cyclophosphamide

Drug: Doxorubicin

Drug: Vincristine

Drug: Prednisolone

Treatment of newly diagnosed peripheral T-cell lymphoma

NCT03631862

Newly diagnosed peripheral T-cell lymphoma

Recruiting

Phase 4

Drug: Apatinib

Drug: CHOP Regimen

Efficacy and safety of decitabine plus CHOP vs CHOP in patients with untreated peripheral T-cell lymphoma

NCT03553537

Peripheral T-cell lymphoma

Not yet recruiting

Phase 3

Drug: Decitabine

Drug: Cyclophosphamide

Drug: Doxorubicin

Drug: Vincristine

Drug: Prednisone

CC486-CHOP in patients with previously untreated peripheral T-cell lymphoma

NCT03542266

Previously untreated peripheral T-cell lymphoma

Active, not recruiting

Phase 2

Drug: CC-486 Administration

Drug: CHOP Administration

Chidamide with CHOP regimen for de Novo PTCL patients (CHOP: cyclophosphamide, etoposide, vincristine and prednisone; PTCL: Peripheral T cell lymphoma)

NCT03268889

Peripheral T-cell lymphoma

Recruiting

Not applicable

Drug: Chidamide

Clinical trial of chidamide combined with CHOP in peripheral T-cell lymphoma patients

NCT02809573

Peripheral T-cell lymphoma

Completed

Phase 1

Drug: Chidamide

Drug: cyclophosphamide

Drug: adriacin

Drug: vincristine

Drug: prednisone

A Dose-Finding Study of Folotyn® (pralatrexate injection) Plus CHOP With peripheral T-cell lymphoma (PTCL)

NCT02594267

Peripheral T-cell lymphoma

Active, not recruiting

Phase 1

Drug: Pralatrexate Injection

Compare efficacy of CHOP versus fractionated ICED in transplant-eligible patients with previously untreated PTCL

NCT02445404

Peripheral T-cell lymphoma

Recruiting

Phase 2

Drug: CHOP

Drug: fractionated ICED

Phase 1 dose finding study of belinostat for treatment of patients with peripheral T-cell lymphoma (PTCL)

NCT01839097

Peripheral T-cell lymphoma

Completed

Phase 1

Drug: Belinostat

Drug: CHOP

Efficacy and safety of romidepsin CHOP vs CHOP in patients with untreated peripheral T-cell lymphoma

NCT01796002

Peripheral T-cell lymphoma

Active, not recruiting

Phase 3

Drug: Romidepsin + CHOP

Drug: CHOP

ECHELON-2: a comparison of brentuximab vedotin and CHP with standard-of-care CHOP in the treatment of patients with CD30-positive mature T-cell lymphomas

NCT01777152

Anaplastic large-cell lymphoma

Non-Hodgkin lymphoma

T-cell lymphoma

Active, not recruiting

Phase 3

Drug: brentuximab vedotin

Drug: CHOP/CHP

CHOP vs GEM-P in 1st line treatment of T-cell lymphoma, multicentre phase II study

NCT01719835

Peripheral T-cell lymphoma NOS

Anaplastic large cell lymphoma, ALK-negative

Angioimmunoblastic T-cell lymphoma

Hepatosplenic Gamma/Delta T-cell lymphoma

Enteropathy-associated T-cell lymphoma

Active, not recruiting

Phase 2

Drug: Cyclophosphamide

Drug: Gemcitabine

Drug: Doxorubicin

Drug: Vincristine

Drug: Prednisolone

Drug: methylprednisolone

Drug: Cisplatin

Intensive chemo-immunotherapy as first line treatment in adult patients with peripheral T-cell lymphoma

NCT01679860

Lymphoma, T-cell, peripheral

Completed

Phase 2

Procedure: Clin A. CHOP-CAMPATH (Chemo-immunotherapy) + SCT

Drug: Clin B (CHOP-CAMPATH) Chemo-immunotherapy

Treatment of peripheral T-cell lymphoma

NCT01664975

Peripheral T-cell lymphoma

Completed

Phase 4

Drug: GDPT regimen

Drug: CHOP regimen

Study of pralatrexate versus observation following CHOP-based chemotherapy in previously undiagnosed peripheral T-cell lymphoma patients

NCT01420679

Peripheral T-cell lymphoma

Terminated

Phase 3

Drug: Pralatrexate injection

A phase 3 trial of E7777 in combination with CHOP compared with CHOP alone for the first-line treatment of peripheral T-cell lymphoma

NCT01355783

Peripheral T-cell lymphoma

Withdrawn

Phase 3

Drug: E7777

A study of escalating doses of romidepsin in association with CHOP in the treatment of peripheral T-cell lymphomas

NCT01280526

Peripheral T-cell lymphoma

Completed

Phase 1/Phase 2

Drug: Romidepsin and CHOP

RAD001 combined with CHOP in newly diagnosed peripheral T-cell lymphomas

NCT01198665

Peripheral T-cell lymphoma unspecified

Anaplastic large cell lymphoma, ALK-negative

Angioimmunoblastic T cell lymphoma

Cutaneous T cell lymphoma

Completed

Phase 1/Phase 2

Drug: RAD001 (Everolimus)

Safety study of darinaparsin in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) to treat lymphoma

NCT01139359

Lymphoma

Withdrawn

Phase 1

Drug: darinaparsin

Drug: CHOP

Endostar combined with CHOP regimen as first line chemotherapy for peripheral T cell lymphoma

NCT00974324

T cell lymphoma

Unknown

Phase 2

Drug: endostar and CHOP

The effectiveness of alemtuzumab given in combination with CHOP and ESHAP in patients newly diagnosed with peripheral T-cell lymphoma (PTCL)

NCT00930605

Peripheral T-cell lymphoma

Completed

Phase 2

Drug: CHOP regimen alternate with ESHAP regimen

Drug: Alemtuzumab

CD4 in combination with CHOP in treating non-cutaneous peripheral T cell lymphoma

NCT00893516

T-cell Lymphoma

Terminated

Phase 2

Biological: CHOP + CD4

Drug: CHOP

SAHA + CHOP in untreated T-cell non-Hodgkin's lymphoma

NCT00787527

Lymphoma

Completed

Phase 1/Phase 2

Drug: Zolinza (vorinostat)

Drug: Cyclophosphamide

Drug: Doxorubicin

Drug: Vincristine

Drug: Prednisone

Immunotherapy in peripheral T cell lymphoma—the role of alemtuzumab in addition to dose dense CHOP

NCT00725231

Peripheral T cell lymphoma, unspecified

Angioimmunoblastic lymphadenopathy

Extranodal NK/T-cell Lymphoma

Unknown

Phase 3

Biological: alemtuzumab

Drug: chemotherapy

Alemtuzumab and CHOP in T-cell lymphoma

NCT00646854

Lymphoma, T-cell, peripheral

Completed

Phase 3

Drug: CHOP14 chemotherapy (cyclophosphamide, hydroxydaunorubicin, vincristin, prednison) plus G-CSF, combined with alemtuzumab

Drug: CHOP14 chemotherapy (see specification under Arm B) plus G-CSF

Alemtuzumab and CHOP chemotherapy for aggressive histological peripheral T-cell lymphomas

NCT00453427

Peripheral T-cell lymphomas

Completed

Phase 1/Phase 2

Drug: Alemtuzumab (Campath-1H)

The effectiveness of alemtuzumab combination with CHOP to treat patients newly diagnosed with PTCL

NCT00441025

Peripheral T-cell lymphoma

Terminated

Phase 2

Drug: Alemtuzumab

Bortezomib and CHOP in patients with advanced stage aggressive T cell or natural killer (NK)/T cell lymphomas

NCT00374699

Peripheral T-cell lymphomas

Non-hodgkin lymphoma

Completed

Phase 1/Phase 2

Drug: Velcade

A pilot study to determine the safety of the combination of Ontak in combination with CHOP in peripheral T-cell lymphoma

NCT00337987

Peripheral T-cell lymphoma

Completed

Phase 2

Drug: Ontak

Drug: CHOP (cyclophosphamide (C), adriamycin (H), vincristine (O), and prednisone (P)) chemotherapy

A study of ONTAK and CHOP in newly diagnosed, peripheral T-cell lymphoma

NCT00211185

Lymphoma, T-cell, peripheral

Completed

Phase 2

Drug: Denileukin diftitox

Drug: Cyclophosphamide

Drug: Doxorubicin

Drug: Vincristine

Drug: Prednisone

Other: Pegfilgrastim

  1. The detail show on https://clinicaltrials.gov/